- Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
- Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
- Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
- Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
- Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
More ▼
Key statistics
On Wednesday, Amylyx Pharmaceuticals Inc (AMLX:NSQ) closed at 1.77, 12.38% above the 52 week low of 1.58 set on Jun 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.75 |
---|---|
High | 1.79 |
Low | 1.69 |
Bid | 1.75 |
Offer | 1.77 |
Previous close | 1.74 |
Average volume | 2.95m |
---|---|
Shares outstanding | 68.01m |
Free float | 58.03m |
P/E (TTM) | -- |
Market cap | 120.37m USD |
EPS (TTM) | -1.07 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼